Innovacion y Desarrollo de Estrategias en Salud
Quick facts
Phase 3 pipeline
- Montelukast mixed with Loratadine · Immunology / Allergy
This combination blocks cysteinyl leukotriene receptors (montelukast) and histamine H1 receptors (loratadine) to reduce allergic inflammation and symptoms.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Innovacion y Desarrollo de Estrategias en Salud portfolio CI brief
- Innovacion y Desarrollo de Estrategias en Salud pipeline updates RSS
Frequently asked questions about Innovacion y Desarrollo de Estrategias en Salud
What is Innovacion y Desarrollo de Estrategias en Salud's pipeline?
Innovacion y Desarrollo de Estrategias en Salud has 1 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include Montelukast mixed with Loratadine.
Related
- Sector hub: All tracked pharma companies